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HORMONES – CYTOKINES – SIGNALING
Cyclooxygenase metabolites mediate glomerular
monocyte chemoattractant protein-1 formation and
monocyte recruitment in experimental glomerulonephritis1
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Cyclooxygenase metabolites mediate glomerular monocyte cytokines called chemokines exhibit strong chemotactic
chemoattractant protein-1 formation and monocyte recruit- activities and is involved in inflammatory cell recruit-
ment in experimental glomerulonephritis.
ment into injured tissues [2, 3]. Among the chemokines,Background. Monocyte chemoattractant protein-1 (MCP-1)
members of the -C-C- group, such as monocyte chemoat-has been shown to play a significant role in the recruitment of
monocytes/macrophages in experimental glomerulonephritis. tractant protein-1 (MCP-1), are strong attractants for
Whereas a number of inflammatory mediators have been char- monocytes [4]. Expression of MCP-1 has been demon-
acterized that are involved in the expression of MCP-1 in renal
strated in glomeruli of animals and humans with glomer-disease, little is known about repressors of chemokine forma-
ulonephritis and is involved in the monocyte/macro-tion in vivo. We hypothesized that cyclooxygenase (COX)
products influence the formation of MCP-1 and affect inflam- phage (M/M) infiltration into glomeruli and the renal
matory cell recruitment in glomerulonephritis. interstitium [5–8]. The regulation of MCP-1 formationMethods. The effect of COX inhibitors was evaluated in the
in glomerulonephritis, however, and the resulting patho-antithymocyte antibody model and an anti-glomerular base-
ment membrane model of glomerulonephritis. Rats were treated physiological consequences are unclear.
with the COX-1/COX-2 inhibitor indomethacin and the selec- Recent in vitro studies of cultured mesangial cells have
tive COX-2 inhibitors meloxicam and SC 58125. Animals were shown that several mediators of inflammation such asstudied at 1 hour, 24 hours, and 5 days after induction of the
cytokines and growth factors can stimulate the releasedisease.
Results. Indomethacin, to a lesser degree the selective COX-2 of MCP-1 [9–11]. In contrast, only a few repressors of
inhibitors, enhanced glomerular MCP-1 and RANTES mRNA MCP-1 expression have been described [12, 13]. In a rat
levels. Indomethacin enhanced glomerular monocyte chemoat-
model of antithymocyte antiserum-induced glomerulo-tractant activity an the infiltration of monocytes/macrophages
nephritis, the glomerular MCP-1 expression is reducedat 24 hours and 5 days.
Conclusions. Our studies demontrate that COX products by prostaglandin E (PGE) [14]. These studies suggest
may serve as endogenous repressors of MCP-1 formation in that endogenously formed prostaglandins can modulate
experimental glomerulonephritis. The data suggest that COX-1
the formation of MCP-1 and influence the clinical out-and COX-2 products mediate these effects differently because
come of the disease.the selective COX-2 inhibitors had less influence on chemokine
expression. The major enzyme regulating the synthesis of prosta-
glandins is cyclooxygenase (COX) [15]. Two isozymes
of COX, COX-1 and COX-2, have been characterized.
The infiltration and accumulation of leukocytes in glo-
COX-1 is a constitutive enzyme present in many mam-meruli and the tubulointerstitium are typical pathological
malian cells [15, 16]. It is assumed that its products arefeatures of most immune-mediated glomerular injuries
important for the maintenance of normal functions in[1]. Recent experimental studies suggest that a group of
the kidney. COX-2 is undetectable in most mammalian
tissues, but its expression can be rapidly and transiently1 See Editorial by Breyer, p. 738.
induced by cytokines and growth factors in different cell
Key words: leukocytes, glomerular injury, inflammation, COX-2, types [17–19], including glomerular mesangial cells [20,
chemokine, monocyte chemoattractant protein-1, enzyme. 21]. These data suggest that COX-2 plays a major role in
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the rapid production of prostaglandins during inflamma- rabbits (Charles River) by repeated immunization with
thymocytes from Lewis rats (Charles River). The speci-tory processes.
The assumption that COX products might be involved ficity of the antibodies was tested in vitro and in vivo
for their reactivity with mesangial cells. Details of thein the regulation of MCP-1 production must therefore
include the consideration of products from both enzyme immunization as well as the characterization of the anti-
serum were described earlier [26]. The glomerulonephri-isoforms.
To investigate the possible role of COX-1 and COX-2 tis that develops after the intravenous administration of
the antibody is characterized by an immune complexproducts in the glomerular formation of MCP-1 and the
pathophysiological consequences, the effects of an un- formation on mesangial cells, complement activation,
and an infiltration of polymorphonuclear granulocytesspecific COX-1/COX-2 inhibitor (indomethacin) and
two selective COX-2 inhibitors [meloxicam (Mel) and and monocytes, resulting in mesangiolysis that is fol-
lowed by mesangial cell proliferation and an increaseSC 58125] were studied in two different models of glo-
merulonephritis in rats. A rat model of mesangial prolif- in extracellular matrix. The morphologic and functional
characteristics of this glomerular lesion have been de-erative glomerulonephritis was studied at different time
points after induction of the disease. The data were then scribed earlier [26].
Anti-GBM nephritis. Nephritis was induced in maleconfirmed in a model displaying a similar time frame
of MCP-1 expression, a rat model of anti-glomerular Wistar rats (120 to 150 g body wt) by i.v. injection of 0.5
ml per 100 g body wt of a rabbit antirat glomeruli serum.basement membrane (GBM) nephritis.
Additionally, another -C-C- chemokine that may be The anti-GBM serum was induced in New Zealand rab-
bits by repeated immunization (four times) with a ratinvolved in the recruitment of macrophages in glomeru-
lonephritis, RANTES, was investigated [22]. GBM preparation. For each immunization, glomeruli
derived from two rat kidneys (1.0 g each) were isolatedThe data reveal that the nonselective COX-inhibitor
indomethacin stimulated the glomerular expression of using a differential sieving technique as described earlier
[27]. Glomeruli were washed twice in cold phosphate-MCP-1 and RANTES mRNA. This was paralleled by
sustained glomerular recruitment of M/M. The selective buffered saline (PBS) and were collected in 1 ml of PBS.
Then glomeruli were homogenized in a Wheaton dounceinhibitors of COX-2 showed little effect on chemotactic
activity and cell infiltration. tissue homogenizer (Wheaton, Millville, NJ, USA) using
a loose fit pestel. Glomerular homogenate was sonifiedThese findings suggest that the expression of glomeru-
lar MCP-1 might be repressed by COX products. The twice for 10 seconds (Branson Sonifier 250; Branson,
Danbury, CT, USA) at 20% energy output level. Aftersustained glomerular MCP-1 formation with indometha-
cin, which is associated with enhanced chemotactic activ- sonification, the preparation was subjected to a second
dounce homogenization using a tight fit pestle. One milli-ity and an increased recruitment of M/M into glomeruli,
underlines the important role of this chemokine in M/M liter of glomerular homogenate containing rat GBM
fragments was mixed with 0.5 ml of immunizing adju-infiltration in glomerulonephritis and demonstrates an
important contribution of COX products as endogenous vants (Hunter’s Titer Max; Boehringer Ingelheim Bio-
products, Heidelberg, Germany), and rabbits were in-repressors of this proinflammatory cytokine.
jected with this preparation. One week after the last
immunization, rabbits were bled. The antiserum was heat
METHODS
inactivated and was kept frozen at 2208C in aliquots.
Compounds Antigen specificity was evaluated for each antibody
preparation in vivo for their reactivity with GBM (dataMeloxicam and SC 58125 were gifts from Dr. Karl
Thomae, Boehringer Ingelheim GmbH, Germany. Mel not shown). The glomerulonephritis that develops after
the intravenous administration of the antibody is charac-[23] and SC 58125 [24] are newly developed compounds
that preferentially inhibit the COX-2 isoform. For that terized by a linear deposition of antibodies at the GBM,
complement activation, and an infiltration of polymor-reason, they are called selective COX-2 inhibitors. Indo-
methacin, known to inhibit both COX isoforms with a phonuclear granulocytes and monocytes.
slight selectivity for COX-1 [25], was purchased from
Animal groups and experimental protocolSigma Chemicals (Deisenhofen, Mu¨nchen, Germany).
ATS nephritis. Five groups of animals were studied
Induction of glomerulonephritis at each time point. Four animals were studied per group
at each time point. All time points were investigated atAntirat thymocyte serum (ATS) nephritis. Immune-
mediated mesangial cell injury was induced in male least twice. Experiments in anti-GBM nephritis were
carried out only at five days after induction of the diseaseWistar rats (120 to 150 g body wt; Charles River, Sulzfeld,
Germany) by i.v. injection of 0.5 ml per 100 g body wt with four groups of animals, consisting of five animals
in each group.of a rabbit ATS. ATS was induced in New Zealand
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Control rats received 0.5 ml per 100 g body wt of International, Temecula, CA, USA). Tissue sections were
developed with the alkaline phosphatase antialkalinenonantibody IgG intravenously.
All nephritic rats received 0.5 ml per 100 g body wt phosphatase technique. The appearance of ED-1–positive
cells was assessed by counting positive cells in at leastof antithymocyte serum or 0.4 ml per 100 g body wt of
anti-GBM antiserum, respectively, intravenously. Con- 50 glomeruli per kidney by light microscopy in a blinded
fashion. Eight different kidneys of each group were eval-trol and nephritic rats received 0.5 ml of 1% methylcellu-
lose orally twice daily. uated at 24 hours and 5 days in the ATS experiments,
and five different kidneys of each group at five days inNephritic rats treated with Mel received 2 mg/kg body
wt of Mel in 0.5 ml 1% methylcellulose orally twice the anti-GBM experiment. The cell numbers of ED-1–
positive cells are given per glomerular cross section asdaily. Nephritic rats treated with SC 58125 (only in ATS
nephritis) received 2 mg/kg body wt of SC 58125 in 0.5 means 6 sem.
ml 1% methylcellulose orally twice daily. This dose was
Isolation of total RNAchosen because of its reported anti-inflammatory effect
and Northern blot hybridization[24]. In another set of experiments in ATS nephritis, rats
received either 3 mg/kg or 6 mg/kg body wt of SC 58125 After isolation of glomeruli, cellular RNA from four
to six pooled kidneys was prepared by the guanidiniumin 0.5 ml 1% methylcellulose orally twice daily. Nephritic
rats treated with indomethacin received 6 mg/kg body isothiocyanate method [28]. Twenty-five micrograms of
total RNA were electrophoresed through a 1.2% agarosewt (2 mg/kg body wt in the group treated for five days) of
indomethacin in 0.5 ml of a 5% buffered 0.5 m Na2HPO4/ gel containing 2.2 m formaldehyde. Equal loading of
lanes was evaluated by ethidium bromide staining of theNaH2PO4 solution orally twice daily. In all groups, oral
medication was started 12 hours before induction of the 18S and 28S rRNA. The RNA was transferred to nylon
membranes (Zetabind; Cuno, Meriden, CT, USA) bydisease and continued until sacrifice.
One hour, 24 hours, and 5 days following the applica- vacuum blotting and was UV cross-linked. The mem-
branes were hybridized with a cDNA probe for a rattion of the antibody, animals were sacrificed for collec-
tion of renal tissue. Kidneys were removed after perfu- 0.42 kb MCP-1 fragment [29] or a cDNA probe for a
murine 0.6 kb RANTES fragment [30] after [32P]dCTP-sion in situ with 50 ml 1 3 PBS. Glomeruli were isolated
from each kidney by a fractional sieving technique as labeling by random oligonucleotide priming of the
cDNA insert in RapidHyb-buffer (Amersham, Braun-described elsewhere [27]. Glomeruli were then separated
for extraction of total RNA, Western blotting, and incu- schweig, Germany) for 18 hours at 728C. The membranes
were washed in 2 3 SSC 2 0.5% SDS (20 3 SSC is 3 mbation with cell culture medium. At 1 hour, 24 hours,
and 5 days, tissue from one kidney of each rat was col- sodium chloride 2 0.3 m sodium citrate) for 20 minutes
at room temperature, then in 0.4 3 SSC 2 0.5% SDSlected for histologic evaluation. Urine excretion over 12
hours was collected in metabolic cages. The urines were and subsequently in 0.1 SSC 2 0.1% SDS at 728C for
20 minutes each. Autoradiography was performed withcentrifuged at 3,500 r.p.m. for five minutes and were
frozen at 2208C until determination of PGE2. intensifying screens at 2708C for 2 to 24 hours. The size
of the respective RNA was identified by comparison
Histology of its mobility with the ethidium bromide-stained RNA
standards. The membranes were stripped for 20 minutesIn the ATS experiments, renal tissue was obtained from
all animals at 1 hour, 24 hours, and 5 days following in 5 mm Tris-HCl (pH 8.0), 0.5% sodium pyrophosphate,
5 3 Denhardt’s solution, and 0.2 mm ethylenediaminetet-induction of the disease to assess binding of ATS and
complement C3 and to evaluate glomerular M/M infil- raacetic acid (pH 8.0) at 658C and were rehybridized
with a 0.58 kb Eco RI cDNA probe encoding for humantration. In the anti-GBM experiment, renal tissue was
obtained from all animals at 5 days following induction 18S rRNA to account for small loading and transfer
variations. Exposed films were scanned with a laser den-of the disease to assess deposition of antiserum and to
evaluate glomerular M/M infiltration. The tissue was sitometer (Hoefer Scientific Instruments, San Francisco,
CA, USA), and relative RNA levels were calculated.fixed in 4% buffered formaldehyde and in methyl Car-
noy’s solution, respectively. To control for ATS, anti- Results are given as the mean of the independent investi-
gations.GBM antiserum, and rat C3 binding in kidneys, paraffin-
embedded tissue sections (2 mm) were stained with a
Determination of PGE2goat antibody directed against rabbit IgG (Dakopatts,
in the supernatant of isolated glomeruliHamburg, Germany) and a mouse monoclonal antibody
against rat C3 (Nordic, Tilborg, the Netherlands). To After isolation, glomeruli of one-half kidney were in-
cubated with 1.5 ml RPMI 1640 tissue culture mediumanalyze the infiltration of M/M into nephritic glomeruli,
kidney tissue was stained with an antibody directed at 378C for 40 minutes. To determine if there was a
possible inhibition of PGE2 production by COX inhibi-against the monocyte-specific marker ED-1 (Chemicon
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tors in vitro, either indomethacin (1 mm) or Mel (1 mm) partment of the chambers. Monocytes (500 ml, 1.75 3
106 cells) were added to the upper compartments abovewere added to the medium of incubation. After centrifu-
gation at 3,500 r.p.m. for 10 minutes, the supernatant was the filters. The chambers were incubated at 378C for 90
minutes in a humidified 5% CO2 atmosphere. The filterscollected, and glomeruli and supernatant were frozen at
2208C until determination of protein and PGE2. Protein were removed and were stained with Giemsa, and che-
motaxis was assayed by counting the number of cells onwas determined after solubilizing glomeruli in 0.5 n
NaOH using a BioRad Protein assay. PGE2 was deter- the attractant side of the filter in 10 oil-immersion fields.
Chemotactic activity is expressed as the mean numbermined using a PGE2 EIA (Cayman Chemical Co., Ann
Arbor, MI, USA). The results are expressed as pg PGE2 of monocytes migrating per field and per mg glomerular
protein.per mg total cell protein per minutes.
Determination of urinary PGE2 Western blots of COX-1 and COX-2
For Western blotting, glomeruli were isolated and cen-Prostaglandin E2 concentration in the urine from ani-
mals placed in metabolic cages overnight (12 hours) was trifuged in 1 3 PBS. A modification of Western blotting
[32] was used as follows. The pellet was resuspended indetermined using the PGE2 EIA (Cayman Chemical
Co.). The total amount of PGE2 in the urine was calcu- 150 ml of Laemmli buffer 1 (33% 0.5 mm Tris-HCl pH
6.8, 66% SDS 10%). Samples were boiled for 10 minuteslated by multiplication of the measured concentration
by the volume of the excreted urine. Results are ex- and were centrifuged. The protein concentration was
determined with a modified Lowry method (Protein DC-pressed as pg PGE2.
assay; Biorad). To equal amounts of protein (100 mg),
Monocyte chemotactic activity 1/4 vol% Laemmli buffer 2 (50% b-mercaptoethanol,
in conditioned media of isolated glomeruli 50% glycerol) and 1/5 vol% staining solution (42.5%
glycerol, 0.5% bromphenol blue) were added. The solu-To study the release of chemotactic activity from glo-
meruli at 24 hours and 5 days after induction of the ATS tion was electrophoresed on a 8% SDS/polyacrylamide
gel. A low molecular weight marker (Rainbow marker;glomerulonephritis and 5 days after induction of the anti-
GBM nephritis, glomeruli from control rats, nephritic Amersham), which compromises 14.3 to 200 kDa, served
as the molecular-weight standard. A mouse macrophagerats, and nephritic rats treated with Mel, SC 58125 (not
in anti-GBM nephritis), and indomethacin, respectively, cell lysate served as a positive control for COX-2. After
the completion of electrophoresis, proteins were elec-were isolated as described earlier here. Following isola-
tion, glomeruli of approximately one kidney were incu- troblotted semidry (Anode buffer I: 30 mm Tris, 20%
methanol; Anode buffer II: 300 mm Tris, 20% methanol;bated in serum-free Dulbecco’s modified Eagle’s medium
for 4.5 hours at 378C in 5% CO2/95% air. Conditioned Cathode buffer: 25 mm Tris, 40 mm 6-aminohexane acid,
20% methanol) for 60 minutes at 0.8 mA/cm2 to a nitro-media and glomeruli were collected following centrifuga-
tion of the glomeruli and frozen at 2208C until evalua- cellulose membrane (Hybond ECL; Amersham). The
membrane was blocked with 5% nonfat dry milk in wash-tion for chemotactic activity. Glomeruli of each prepara-
tion were counted, and the protein content of collected ing buffer (1 3 PBS, 0.1% Tween 20) for one hour at
room temperature and then was incubated for anotherglomeruli was determined with a modified Lowry method
(BioRad protein assay) to relate chemotactic activity to hour with a monoclonal IgG 1 mouse-antirat COX-2
antibody (Transduction Laboratories, Lexington, KY,glomeruli and protein content of each preparation.
Monocyte chemotactic activity was determined in USA) in a concentration of 1:250 or a polyclonal goat-
antimouse COX-1 antibody (Santa Cruz Biotechnology,modified Boyden chambers (Poretics, Livermore, CA,
USA) using freshly prepared human peripheral mononu- Santa Cruz, CA, USA) added to a concentration of 1:500
in the same buffer. After rinsing the membrane in wash-clear cells as described earlier [31]. Blood was drawn
into acid-citrate-dextrose and was centrifuged at 550 g ing buffer for 3 3 8 minutes, the secondary antibody, a
rabbit antimouse-immunoglobulin G (Transduction Lab-for 20 minutes. The cell pellet was resuspended in Hank’s
balanced salt solution (HBSS) containing 0.27% dex- oratories) or a rabbit antigoat-immunoglobulin (South-
ern Biotechnology, Birmingham, AL, USA) conjugatedtrose and 0.37% sodium citrate and layered over one
volume of histopaque-1077 (Sigma) and was centrifuged to horseradish-peroxidase was added at a concentration
of 1:1000. The luminescence detection of peroxidase wasat 400 g for 40 minutes. The mononuclear cell layer was
washed in HBSS and was resuspended in RPMI-0.2% performed with the ECL system according to the manu-
facturer’s recommendations (Amersham) after rinsingalbumin to 3.5 3 106 cells/ml. The monocyte cell chemo-
taxis was quantitated on 8 mm pore polycarbonate filters membranes in washing buffer and 1 3 PBS. Films were
exposed 30 seconds to 10 minutes at room temperature.in blind-well chambers (Poretics). Solutions of condi-
tioned media from glomeruli were diluted with RPMI- After final exposure, staining with Ponceau S confirmed
equal transfer of proteins.0.2% albumin, and 200 ml were placed in the lower com-
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Fig. 1. Expression of mRNA of monocyte chemoattractant protein-1
(MCP-1) during the time course of the anti-thymocyte antibody (ATS)
and anti-glomerular basemement membrane (anti-GBM) nephritis.
MCP-1 mRNA levels increased significantly at 3 hours and 24 hours and
returned to almost normal levels at 5 days. Equal loading transfer of each
lane was confirmed by rehybridization against 18S rRNA (not shown).
Statistical analysis
Results are expressed as mean 6 sem unless stated
otherwise. Statistical significance was defined as P , 0.05.
We applied Wilcoxon-Mann-Whitney test to compare
two distinct treatment groups (that is, nephritic vs. con-
trol or nephritic vs. treated nephritic animals).
RESULTS
Northern blotting
Monocyte chemoattractant protein-1 mRNA expres-
sion, evaluated by Northern blotting, increased signifi-
cantly in nephritic animals at 3 hours and 24 hours after
induction of the disease when compared with controls
in both models of glomerulonephritis (ATS and anti-
GBM). At 5 days MCP-1, mRNA levels returned almost
Fig. 2. Expression of mRNA of MCP-1 from isolated glomeruli ofto control levels (Fig. 1).
ATS nephritic rats 1 hour, 24 hours, and 5 days after induction of theIn the ATS nephritis, the pattern of MCP-1 expression disease under the influence of the treatment with the unselective COX-1/
changed markedly under the influence of the COX inhib- COX-2 inhibitor indomethacin (Indo) or the selective COX-2 inhibitors
meloxicam (Mel) or SC 58125 (SC). MCP-1 mRNA levels are increaseditors at 24 hours and 5 days, whereas treatment with
by treatment with indomethacin at 24 hours (twofold), and more signifi-selective and nonselective inhibitors of COX did not cantly at 5 days (fivefold).
significantly modify the expression of MCP-1 mRNA at
one hour (Fig. 2). Indomethacin enhanced the MCP-1
expression at 24 hours (twofold; Fig. 2), an effect that COX-2 inhibitor SC 58125 also enhanced glomerular
was more pronounced at day 5 (fivefold; Fig. 2) when MCP-1 mRNA levels at day 5 (Figs. 3 to 6), and the
compared with untreated nephritic animals. The more differences between the selective compound and unse-
selective COX-2 inhibitors Mel and SC at a dosage of 2 lective COX-1/COX-2 inhibitor indomethacin were di-
mg/kg body wt showed less systematic effects on glomer- minished (SC 58125, twofold at 3 mg/kg and 2.5-fold at 6
ular MCP-1 mRNA levels at 24 hours and 5 days (Fig. 2). mg/kg; indomethacin, 2.7-fold at 2 mg/kg when compared
with untreated nephritis; Fig. 6).However, when used in higher doses, the selective
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an additional experiment, SC 58125 showed less chemo-
tactic activity than indomethacin (24 hr, 2.35 MØ/mg
protein in SC 58125 vs. 5.1 in animals treated with indo-
methacin; 5 days, 1.74 MØ/mg protein in SC 58125 vs. 3.40
in animals treated with indomethacin) (see also Fig. 5).
In the anti-GBM model, the monocyte chemotactic
activity of conditioned media from glomeruli of nephritic
animals treated with indomethacin was higher when com-
pared with untreated nephritic animals at 5 days (1.48
MØ/mg protein in indomethacin-treated glomeruli vs.
0.55 in untreated nephritic glomeruli; Table 1).
Western blot analysis for COX-1 and COX-2
The influence of unselective COX-1/COX-2 and selec-
tive COX-2 inhibition on glomerular COX-1 and COX-2
protein levels was evaluated in both the ATS and anti-Fig. 3. Expression of MCP-1 mRNA from isolated glomeruli of rats 5
GBM nephritis at 5 days following the induction of thedays after induction of the anti-GBM nephritis under the influence of
treatment with the unselective COX-1/COX-2 inhibitor indomethacin disease. COX-1 protein levels were not modified in ne-
(Indo) or the selective COX-2 inhibitor meloxicam (Mel). MCP-1 phritic animals or nephritic animals treated with selectivemRNA levels are increased in nephritic animals and are further en-
hanced by treatment with indomethacin (threefold in comparison to COX-2 inhibitors. Indomethacin markedly reduced glo-
untreated nephritis when corrected for 18S rRNA). merular COX-1 protein levels at 5 days in both models
(Fig. 4A, ATS nephritis; Fig. 4B, anti-GBM nephritis).
COX-2 protein levels were slightly increased by all inhib-
itors in both models (Fig. 4).Similarly, as found in the ATS model, MCP-1 mRNA
expression is also enhanced by indomethacin in the anti-
PGE2 formationGBM nephritis at five days after induction of the disease
Release of PGE2 in the supernatant of isolated glomer-when compared with untreated nephritis (threefold;
uli from controls, ATS nephritic rats and ATS nephriticFig. 3).
RANTES mRNA expression was moderately increased rats treated with indomethacin or Mel at 24 hours and
in glomeruli from nephritic animals at 24 hours, and more 5 days, is shown in Table 2. Because none of the COX
so at 5 days after induction of the disease (data not shown). inhibitors studied bind covalently to the enzymes, release
At 5 days, treatment with indomethacin significantly aug- of PGE2 in the supernatant reflects the enzyme activity
mented RANTES mRNA expression (twofold when com- of in vivo pretreated glomeruli in the absence of the
pared with untreated nephritis). The selective COX-2 inhibitors. At 24 hours following induction of the glomer-
inhibitor SC 58125 induced a smaller increase (1.4-fold ulonephritis, PGE2 release of glomeruli from nephritic
at 3 mg/kg, 1.35-fold at 6 mg/kg body wt when compared animals was not significantly different compared with
with untreated nephritis) of glomerular RANTES ex- controls. At 5 days, however, the PGE2 release from
pression (Fig. 6). nephritic glomeruli was twice as much as from glomeruli
of control animals. Glomeruli isolated at 24 hours fromMonocyte chemotactic activity
animals treated with Mel or indomethacin produced sig-of glomerular supernatants
nificantly more PGE2 when compared with nephritic orIn the ATS model, the monocyte chemotactic activity
untreated animals, an effect that was not seen in glomer-of conditioned media from nephritic glomeruli was sig-
uli isolated at 5 days. To ensure that COX inhibitionnificantly higher when compared with controls at 24
with the drugs used was effective, Mel and indomethacinhours (1.38 MØ/mg protein in nephritic glomeruli vs.
were added at a concentration of 1 mm to the isolated0.53 in controls), but returned to control levels at 5 days
glomeruli of all animal groups studied. Both inhibitors(Table 1). The stimulated chemotactic activity was fur-
significantly reduced prostaglandin formation belowther augmented by indomethacin at 24 hours (4.98 MØ/
baseline control levels (data not shown). To evaluate themg protein vs. 1.38 in controls) and at 5 days (2.34 MØ/
effectivity of the COX inhibitors in vivo, urinary PGE2mg protein vs. 0.63 in nephritic glomeruli). Treatment
excretion was determined at 5 days. At this time point,of the nephritic animals with the selective inhibitors Mel
indomethacin significantly inhibited PGE2 excretion,and SC did not affect chemotactic activity to the same
whereas the selective COX-2 inhibitors Mel and SC diddegree as indomethacin at any time point (Table 1).
Even when used at a higher dose (6 mg/kg body wt) in not (Table 3).
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Fig. 4. Expression of COX-1 and COX-2 pro-
tein levels at five days after induction of the
disease under the influence of the treatment
with the unselective COX-1/COX-2 inhibitor
indomethacin (Indo) or the selective COX-2
inhibitors meloxicam (Mel) or SC 58125 (SC).
Treatment with indomethacin decreases COX-1
protein levels, whereas COX-2 protein levels
are slightly increased. Treatment with SC
58125 or meloxicam does not decrease COX-1
levels. (A ) ATS nephritis. (B ) Anti-GBM ne-
phritis. A mouse macrophage cell lysate (*)
served as positive control for COX-2 protein.
Histology tion in glomerulonephritis [5–8, 33]. In the antithymocyte
antibody-induced model of glomerulonephritis, the ex-Induction of ATS nephritis was followed by glomeru-
pression of MCP-1 is positively correlated with the infil-lar infiltration of ED-1–positive cells, with a maximum
tration of M/M in glomeruli, and the disappearance ofat 24 hours (Table 4). Treatment of ATS nephritic rats
MCP-1 expression is followed by a reduction of glomeru-with selective inhibitors of COX-2 did not significantly
lar monocytes [8]. This suggests a regulation of the disap-modify the number of infiltrating ED1(1) cells at 24 hours
pearance of MCP-1 in this disease, either by a reductionor 5 days. In contrast, treatment of ATS nephritic rats
of MCP-1–stimulating factors or by an enhanced or novelwith indomethacin increased the recruitment of ED1(1)
appearance of repressive factors of MCP-1 formation,cells significantly both at 24 hours and 5 days (Table 4).
thus contributing to the healing process in this disease.Additional experiments in the anti-GBM nephritis
A better understanding of the regulation of stimulatingalso show that treatment with indomethacin significantly
or repressing factors might be important for the develop-increased the number of infiltrating ED1 (1) cells at 5
ment of therapeutic strategies. In contrast to the largedays after induction of the nephritis (Table 4).
number of proinflammatory mediators that have been
suggested as being responsible for the stimulation of
DISCUSSION MCP-1 in glomerulonephritis [9–11], so far no informa-
tion is available on potential repressors of MCP-1 thatMonocyte chemoattractant protein-1 is a chemokine
that plays an important role in monocyte chemoattrac- might be operative even in the situation of persistently
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Fig. 5. Kidney sections showing typical glomeruli from control rats (A),
ATS nephritic rats (B ), and ATS nephritic rats treated with indometha-
cin (C ) at five days after induction of the ATS nephritis. The number
of ED-1 positive cells (red) is enhanced in nephritic animals treated
with indomethacin (C ).
increased proinflammatory mediators. Such hypothetical merulonephritis were treated with COX inhibitors, and
the formation of MCP-1 was evaluated in glomeruli inendogenous repressors might be responsible for a down-
regulation of MCP-1 expression with the consecutive conjunction with histologic studies. To study whether
possible changes have a more general role in glomerulo-effect of diminished M/M recruitment. Recent evidence
in cell culture studies [11] and in vivo experiments in nephritis, we added experiments in another model dis-
playing a similar pattern of MCP-1 expression (Fig. 1),the anti-thy-1 model [14] indicate that PGs of the E
series suppress the formation of MCP-1 and reduce the the anti-GBM nephritis in rats. To control for a possible
similar regulation of other chemokines involved in the re-infiltration of inflammatory cells into glomeruli. Because
prostaglandins are major local products in the kidney cruitment of inflammatory cells, expression of RANTES
was evaluated under the influence of COX inhibition in[34], they might serve as endogenous repressors of MCP-1.
To test this hypothesis, rats with the ATS-induced glo- the ATS model. As for MCP-1, there was a similar rise
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Table 1. Monocyte chemotactic activity
Time Monocytes sd
Control 0.53 0.26
ATS 24 hours 1.38 0.13
ATS 1 Mel 24 hours 2.20 1.51
ATS 1 Indo 24 hours 4.98 2.38a
ATS 5 days 0.63 0.20
ATS 1 Mel 5 days 0.54 0.08
ATS 1 Indo 5 days 2.34 1.30b
ATS 1 SC 5 days 0.69 0.15
Control 0.47
Anti-GBM 5 days 0.55
Anti-GBM 1 Mel 5 days 0.91
Anti-GBM 1 Indo 5 days 1.48
Monocyte chemotactic activity of conditioned media from glomeruli of control,
nephritic, and nephritic animals treated with COX-inhibitors [indomethacin
(Indo), meloxicam (Mel), SC 58125 (SC)] isolated at 24 hours and 5 days after
induction of the antirat thymocyte serum (ATS) nephritis and at 5 days of the
anti-GBM nephritis. ATS animals revealed an increase of chemotactic activity at
24 hours but returned to control levels at 5 days. Indomethacin further enhanced
chemotactic activity at 24 hours and 5 days, whereas SC 58125 and meloxicam
had no effect. Data are given as the mean number of migrated monocytes/high
power field/mg glomerular protein from 3 different experiments. Additional
experiments in the anti-GBM nephritis also reveal an enhanced glomerular-
derived chemotactic activity by treatment with indomethacin at 5 days.
a P 5 0.01 vs. ATS
b P 5 0.05 vs. ATS and vs. ATS 1 Mel or 1 SC
Fig. 6. Expression of MCP-1 and RANTES mRNA from isolated Table 2. Prostaglandin E2 (PGE2) release from isolated glomeruli
glomeruli of rats five days after induction of the ATS nephritis under
PGE2the influence of treatment with the unselective COX-1/COX-2 inhibitor
Time pg/min /mg protein sdindomethacin (Indo, 2 mg/kg body wt) or the selective COX-2 inhibitor
SC 58125 at higher doses (SC1 3 mg/kg, SC2 6 mg/kg body wt). Indo- Control 11.63 5.90
methacin increases MCP-1 mRNA levels (threefold) and RANTES Nephritis 24 hours 8.87 3.30
mRNA levels (twofold) in comparison to untreated nephritic animals. Nephritis 1 Mel 24 hours 27.70 13.80a
SC 58125 shows a dose-dependent effect, increasing MCP-1 levels Nephritis 1 Indo 24 hours 22.67 8.40a
twofold at 3 mg/kg and 2.5-fold at 6 mg/kg, an effect that is less
Control 10.38 2.61pronounced for RANTES mRNA levels (SC1 1.4-fold, SC2 1.35-fold)
Nephritis day 5 21.24 13.60when compared with untreated nephritic animals.
Nephritis 1 Mel day 5 29.91 13.60
Nephritis 1 Indo day 5 34.77 11.73b
Nephritis 1 SC day 5 16.14 6.27
PGE2 release in the supernatants of isolated glomeruli from control rats,in mRNA expression of RANTES under the influence nephritic rats, and nephritic rats treated with indomethacin (Indo) or meloxicam
(Mel). At 24 hours there was less glomerular PGE2 production in nephritic ratsof COX inhibition. These data suggest that COX products
than in controls, at 5 days nephritic glomeruli produced twice as much PGE2 as
do effect the expression of more than one chemokine. controls; however, these effects did not reach statistical significance. Animals
treated with either Indo or Mel released more prostaglandins than nephritic ratsThe major findings of our study are that the unselective
at 24 hours, an effect that was not significant at 5 days. Results are expressed
COX-1/COX-2 inhibitor indomethacin increases the as pg PGE2/min of incubation time/mg of glomerular protein. PGE2 release in
the supernatants was significantly inhibited in all groups to levels below 5.24 pg/MCP-1 mRNA expression, enhances the release of che-
min/mg protein when indomethacin or meloxicam were added in vitro to the
moattractant activity, and augments the M/M infiltration medium of incubation at a concentration of 1 mm (data not shown).
a P , 0.001 vs. nephritisin glomeruli of nephritic animals. We suggest that indo- b P , 0.03 vs. nephritis 1 SC
methacin exerts these effects by reducing the in vivo
production of renal prostaglandins and that this can be
attributed to the blockade of COX products. This sugges-
tion is supported by the observation that PGE2 produc- ment of MCP-1 expression. The enhanced MCP-1 forma-
tion, as the main COX product of the glomerulus [34], tion has functional and morphological consequences,
is maximal at day 5 (Table 2) where almost no MCP-1 that is, an increased production of glomerular chemotac-
expression is detectable, whereas MCP-1 and chemotac- tic activity and a stimulated recruitment of M/M into the
glomeruli. COX products in the glomerulus may there-tic activity is maximal (Table 1) when PGE2 is almost
unchanged or reduced (24 hr). Thus, it would appear fore serve as endogenous repressors in the regulation of
MCP-1 formation and may contribute to the healingthat enhanced PG formation is correlated with a reduced
MCP-1 appearance. This functional relationship is un- process in this disease. Our data do not define which
COX product may mediate MCP-1 expression; however,masked by indomethacin causing the persistent enhance-
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Table 3. PGE2 excretion in the urine affect chemokine transcription will be addressed in sepa-
rate experiments.PGE2 pg sd
Because recent evidence from other models of in-Control 15756 6854
flammatory kidney diseases revealed that particularlyNephritis 12591 10615
Nephritis 1 Mel 4892 1244 products of COX-2 are important in inflammation [37,
Nephritis 1 Indo 3086 965ab 38] and because indomethacin is an unselective COX-1/Nephritis 1 SC 12546 4888
COX-2 inhibitor, we tried to further investigate whether
PGE2 excretion in the urine of control rats, ATS nephritic rats, and ATS one of the isoenzymes COX-1 or COX-2 may account fornephritic rats treated with indomethacin (Indo), meloxicam (Mel), or SC 58125
(SC) placed in metabolic cages overnight at day 5. Indomethacin significantly the repressive activity of MCP-1 formation. In contrast to
reduced PGE2 excretion when compared to all other groups except nephritic the unselective COX-1 and COX-2 inhibitor indometha-rats treated with meloxicam. Results are expressed as pg PGE2.
a P , 0.02 vs. nephritis cin, the two selective COX-2 inhibitors used, Mel and
b P , 0.005 vs. nephritis 1 SC SC, had less effects on chemokine expression. When
higher doses of SC 58125 (6 mg/kg, compared with the 2
mg/kg body wt in other studies) were used, the difference
between indomethacin and SC 58125 on glomerular MCP-1Table 4. Number of monocytes/macrophages in glomeruli
mRNA expression diminished (Fig. 6). However, this dose-
Time ED1(1) cells sd
dependent effect of SC 58125 was less pronounced on
Control 0.19 0.06 chemotactic activity and mRNA expression of RANTES.ATS 24 hours 3.98 0.63
We have no explanation for these differences, but it isATS 1 Mel 24 hours 3.67 0.24
ATS 1 SC 24 hours 3.39 0.55 possible that some effects are due to a possible unselec-
ATS 1 Indo 24 hours 4.90 0.44a tive COX inhibition, because the compounds are not
ATS 5 days 1.50 0.77
fully specific for COX-2 and also inhibit COX-1 at higherATS 1 Mel 5 days 1.30 0.13
ATS 1 SC 5 days 0.81 0.17 doses. Compared with indomethacin, the selective COX-2
ATS 1 Indo 5 days 3.01 0.80b inhibitors at the same concentration as indomethacin (2
Control 0.19 0.04 mg/kg body wt) did not reduce urinary PGE2 production
Anti-GBM 5 days 0.83 0.08 significantly but were able to reduce PGE2 productionAnti-GBM 1 Mel 5 days 1.22 0.30
of isolated glomeruli in vitro, thereby showing biologicalAnti-GBM 1 Indo 5 days 1.88 0.87c
activity. It seems possible that selective COX-2 inhibitionED-1 positive cells per glomerulus (average of 50 glomeruli/kidney, 5 animals
per group) in kidney sections from control, nephritic, and nephritic animals does not contribute to the repressive effects on MCP-1
treated with different COX-inhibitors [indomethacin (Indo), meloxicam (Mel), to the same degree or that COX-2 products do not useSC 58125 (SC)]. M/M infiltration in glomeruli of ATS nephritic rats was signifi-
cantly higher at 24 hours and 5 days compared with controls. Indomethacin the same biosynthetic or signaling pathway as COX-1
significantly increased the appearance of M/M in glomeruli at both time points. products. There is intriguing evidence that, at least inThe selective COX-2 inhibitors were without effect. In the anti-GBM nephritis
indomethacin significantly increased the number of M/M in nephritic glomeruli some cell types, COX-2 is primarily localized in the nu-
at 5 days. clear membrane using a different source of substratea P 5 0.04 vs. nephritis
b P 5 0.02 vs. nephritis 1 Mel, and vs. nephritis 1 SC than COX-1, which is localized in a more diffuse pattern
c P 5 0.02 vs. nephritis in the endoplasmatic reticulum and close to the cell mem-
brane [39]. Inflammatory stimuli may thus activate COX-2,
but COX-2 products may not be released on the surface
of the cells where they can bind to prostaglandin recep-the fact that PGE2 is the major product of rat glomeruli tors, and rather act directly in the nucleus to modulate
[34], together with the results of earlier studies demon-
cell differentiation. Studies in mesangial cell cultures dem-
strating that PGs of the E series can suppress MCP-1 onstrating that the repressive effects of PGE2 on MCP-1expression [14], suggests that PGEs are the primary can- mRNA expression are mediated by a prostacyclin E
didates. The possibility that the changes induced by indo- receptor–coupled stimulation of cyclic AMP [11] together
methacin are independent of COX inhibition still exists. with our results of less modified MCP-1 expression by
We are not aware of data showing that MCP-1 mRNA treatment with COX-2 inhibitors might support our hy-
expression is mediated by any COX-inhibitory drug in- pothesis that primarily COX-1 products regulate MCP-1
dependent of its effects on COXs. in this model of glomerulonephritis.
It is, however, possible that COX inhibitors directly In summary, our data demonstrate that the inhibition
affect the regulation of transcription of chemokines. Aspi- of COX by indomethacin aggravates and maintains the
rin has been shown to inhibit nuclear factor-kB (NF-kB) expression of MCP-1 with consecutive enhancement of
[35], one of the transcription factors that regulates M/M infiltration in two rat models of glomerulonephritis.
MCP-1 expression [36]. We are not aware of data that These data suggest that COX products are important
show that indomethacin or the COX-2 inhibitors used repressors of stimulated MCP-1 in the diseased kidney.
in our experiments have effects on NF-kB. Nevertheless, COX products may thus participate in the M/M clearing
and in the healing process in glomerulonephritis.this important issue of investigating how COX-inhibitors
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